Radiopharmium

Radiopharmium is a specialist UK-based radiopharmaceutical consultancy and contract research organization founded in 2024 by Dr. Louis Allott. The company provides deep expertise in radiochemistry, CMC (Chemistry, Manufacturing, and Controls), GMP process development, and clinical translation for developers and investors in nuclear medicine. Radiopharmium supports clients with tracer design, radiolabeling route selection, and preclinical evaluation across a wide range of isotopes, including F-18, Ga-68, Zr-89, Lu-177, Tb-161, Ac-225, Pb-212, Cu-64, Cu-67, and various iodine isotopes. Additionally, the firm offers fractional scientific leadership (such as fractional CSO/Director roles) and independent due diligence services for life science investors.